{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:57:22Z","timestamp":1761541042277},"reference-count":62,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.bcp.2011.03.015","type":"journal-article","created":{"date-parts":[[2011,4,15]],"date-time":"2011-04-15T00:00:15Z","timestamp":1302825615000},"page":"91-98","source":"Crossref","is-referenced-by-count":20,"title":["Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia"],"prefix":"10.1016","volume":"82","author":[{"given":"Robert G.","family":"Schaub","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2011.03.015_bib0005","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/312342a0","article-title":"Molecular cloning of a cDNA encoding human antihaemophilic factor","volume":"312","author":"Toole","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2011.03.015_bib0010","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/312337a0","article-title":"Structure of human factor VIII","volume":"312","author":"Vehar","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2011.03.015_bib0015","doi-asserted-by":"crossref","first-page":"8302","DOI":"10.1073\/pnas.88.19.8302","article-title":"Physical map of human Xq27-qter: localizing the region of the fragile X mutation","volume":"88","author":"Poustka","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2011.03.015_bib0020","first-page":"66","article-title":"A 1.6-Mb contig of yeast artificial chromosomes around the human factor VIII gene reveals three regions homologous to probes for the DXS115 locus and two for the DXYS64 locus","volume":"51","author":"Freije","year":"1992","journal-title":"Am J Hum Gene"},{"key":"10.1016\/j.bcp.2011.03.015_bib0025","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/317726a0","article-title":"Distribution of factor VIII mRNA and antigen in human liver and other tissues","volume":"317","author":"Wion","year":"1985","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.bcp.2011.03.015_bib0030","doi-asserted-by":"crossref","first-page":"6508","DOI":"10.1021\/bi00394a033","article-title":"Cloning of cDNAs coding for the heavy chain region and connecting region of human factor V, a blood coagulation factor with four types of internal repeats","volume":"26","author":"Kane","year":"1987","journal-title":"Biochemistry"},{"key":"10.1016\/j.bcp.2011.03.015_bib0035","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1055\/s-2003-37935","article-title":"Structure and function of the factor VIII gene and protein","volume":"29","author":"Thompson","year":"2003","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.bcp.2011.03.015_bib0040","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1146\/annurev.bi.49.070180.004001","article-title":"Blood coagulation","volume":"49","author":"Jackson","year":"1980","journal-title":"Ann Rev Biochem"},{"key":"10.1016\/j.bcp.2011.03.015_bib0045","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood.V59.5.1067.1067","article-title":"Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme","volume":"59","author":"Marlar","year":"1982","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2011.03.015_bib0050","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1182\/blood.V63.2.486.486","article-title":"Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V","volume":"63","author":"Fulcher","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2011.03.015_bib0055","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1055\/s-0037-1615621","article-title":"Factor VIII and factor IX subcommittee definitions in hemophilia. Recommendations of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis","volume":"85","author":"White","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.bcp.2011.03.015_bib0060","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJM200106073442307","article-title":"The hemophilias \u2013 from royal genes to gene therapy","volume":"344","author":"Mannucci","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2011.03.015_bib0065","doi-asserted-by":"crossref","first-page":"6461","DOI":"10.1073\/pnas.79.21.6461","article-title":"Isolation and characterization of a cDNA coding for human factor IX","volume":"79","author":"Kurachi","year":"1982","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2011.03.015_bib0070","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/299178a0","article-title":"Molecular cloning of the gene for human anti-haemophilia factor IX","volume":"299","author":"Choo","year":"1982","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2011.03.015_bib0075","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/BF00286666","article-title":"Regional localization of the human factor IX gene by molecular hybridization","volume":"65","author":"Chance","year":"1983","journal-title":"Hum Genet"},{"key":"10.1016\/j.bcp.2011.03.015_bib0080","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1093\/nar\/11.8.2325","article-title":"Isolation of a human anti-haemophilia factor IX cDNA clone using a unique 52-base synthetic oligonucleotide probe deduced from the amino acid sequence of bovine factor IX","volume":"11","author":"Jaye","year":"1983","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.bcp.2011.03.015_bib0085","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/BF01534851","article-title":"Isolation and characterization of human factor IX cDNA: identification of taq I polymorphism and regional assignment","volume":"10","author":"Jagadeeswaran","year":"1984","journal-title":"Somat Cell Mol Genet"},{"key":"10.1016\/j.bcp.2011.03.015_bib0090","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1055\/s-2007-1005094","article-title":"Factor IX complex","volume":"6","author":"Aronson","year":"1979","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.bcp.2011.03.015_bib0095","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1097\/00001721-199304060-00013","article-title":"Biology of factor IX","volume":"4","author":"Kurachi","year":"1993","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.bcp.2011.03.015_bib0100","doi-asserted-by":"crossref","first-page":"5260","DOI":"10.1073\/pnas.74.12.5260","article-title":"Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation","volume":"74","author":"Osterud","year":"1977","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2011.03.015_bib0105","first-page":"394","article-title":"Human coagulation factor IX: assessment of thrombogenicity in animal models and viral safety","volume":"121","author":"Herring","year":"1993","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.bcp.2011.03.015_bib0110","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1365-2141.2005.05854.x","article-title":"Thomas Addis of Edinburgh (1881\u20131949) and the coagulation cascade: \u2018for the greatest benefit done to practical medicine\u2019","volume":"132","author":"Doyle","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bcp.2011.03.015_bib0115","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1172\/JCI100829","article-title":"Some properties of a substance obtained form normal human plasma effective in accelerating the coagulation of hemophilic blood","volume":"16","author":"Patek","year":"1937","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bcp.2011.03.015_bib0120","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3181\/00379727-66-16003","article-title":"Clotting defect in hemophilia: deficiency in a plasma factor required for platelet utilization","volume":"66","author":"Brinkhous","year":"1947","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.bcp.2011.03.015_bib0125","doi-asserted-by":"crossref","first-page":"692","DOI":"10.3181\/00379727-79-19488","article-title":"Plasma thromboplastin component (PTC) deficiency; a new disease resembling hemophilia","volume":"79","author":"Aggeler","year":"1952","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.bcp.2011.03.015_bib0130","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1136\/bmj.2.4799.1378","article-title":"Christmas disease: a condition previously mistaken for haemophilia","volume":"2","author":"Biggs","year":"1952","journal-title":"Br Med J"},{"key":"10.1016\/j.bcp.2011.03.015_bib0135","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/203312a0","article-title":"High-potency antihaemophilic factor concentrate prepared from cryoglobulin precipitate","volume":"203","author":"Pool","year":"1964","journal-title":"Nature"},{"issue":"Suppl. 3","key":"10.1016\/j.bcp.2011.03.015_bib0140","first-page":"1","article-title":"The pharmacokinetics of coagulation factors","volume":"12","author":"Lee","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.bcp.2011.03.015_bib0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/17425240802650568","article-title":"PEG-modified biopharmaceuticals","volume":"6","author":"Bailon","year":"2009","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.bcp.2011.03.015_bib0150","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1182\/blood-2006-03-008276","article-title":"Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes","volume":"108","author":"Spira","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2011.03.015_bib0155","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1538-7836.2007.02856.x","article-title":"Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A","volume":"6","author":"Powell","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.bcp.2011.03.015_bib0160","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1182\/blood-2009-03-212423","article-title":"Enhanced efficacy of recombinant FVIII in noncovalent complex with PEGylated liposome in hemophilia a mice","volume":"114","author":"Pan","year":"2009","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.bcp.2011.03.015_bib0165","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2516.2009.02155.x","article-title":"Longer-acting factor VIII to overcome limitations in haemophilia management: the PEGylated liposomes formulation issue","volume":"16","author":"DiMinno","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.bcp.2011.03.015_bib0170","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1182\/blood-2009-11-254755","article-title":"Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment","volume":"116","author":"Mei","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2011.03.015_bib0175","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1365-2516.2009.02027.x","volume":"15","author":"Recht","year":"2009","journal-title":"Haemophilia"},{"key":"10.1016\/j.bcp.2011.03.015_bib0180","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/j.1365-2516.2010.02333.x","article-title":"Functional characteristics of N8, a new recombinant FVIII","volume":"16","author":"Christiansen","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.bcp.2011.03.015_bib0185","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1365-2516.2009.02135.x","article-title":"Purification and characterization of a new recombinant factor VIII [N8]","volume":"16","author":"Thim","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.bcp.2011.03.015_bib0190","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1182\/blood.V114.22.545.545","article-title":"Factor VIII-Fc fusion protein shows extended half-life and hemostatic activity in hemophilia A dogs","volume":"114","author":"Dumont","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2011.03.015_bib0195","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1182\/blood-2009-08-239665","article-title":"Prolonged activity of factor IX as a monomeric Fc fusion protein","volume":"115","author":"Peters","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2011.03.015_bib0200","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1055\/s-0038-1657536","article-title":"Recombinant factor IX","volume":"78","author":"White","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.bcp.2011.03.015_bib0205","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1111\/j.1538-7836.2009.03560.x","article-title":"Factor IX mutants with enhanced catalytic activity","volume":"7","author":"Hartmann","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.bcp.2011.03.015_bib0210","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa0904377","article-title":"X-linked thrombophilia with a mutant Factor IX [Factor IX Padua]","volume":"361","author":"Simioni","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2011.03.015_bib0215","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1182\/blood-2004-06-2223","article-title":"The use of recombinant factor VIIa in the treatment of bleeding disorders","volume":"104","author":"Roberts","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2011.03.015_bib0220","series-title":"Guidelines for the management of haemophilia","author":"Srivistava","year":"2005"},{"key":"10.1016\/j.bcp.2011.03.015_bib0225","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1161\/01.ATV.0000257204.82396.2b","article-title":"A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolyitc activities in an in vitro model of hemophilia","volume":"27","author":"Allen","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.bcp.2011.03.015_bib0230","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1365-2141.2007.06534.x","article-title":"Factor VIIa analogue (V158D\/E296V\/M298Ql-FVIIa) normalises clot formation in whole blood from patients with severe haemophilia A","volume":"137","author":"Sorensen","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bcp.2011.03.015_bib0235","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1538-7836.2009.03287.x","article-title":"rFVIIa and a new enhanced rFVIIa-analogue NN1731, reduce bleeding in clopidogrel-treated and in thrombocytopenic rats","volume":"7","author":"Lauritzen","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"Suppl. 2","key":"10.1016\/j.bcp.2011.03.015_bib0240","first-page":"222","article-title":"Enhanced and prolonged efficacy of a novel recombinant FVIIa variant (BAY86-6150) for acute and prophylactic treatments in hemophilia A (Hem A) mice","volume":"7","author":"Liu","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.bcp.2011.03.015_bib0245","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1160\/TH09-11-0797","article-title":"Prolonged effect of glycoPEGylated rFVIIa (40k-PEG-rFVIIa) in rabbits correlates to activity in plasma","volume":"104","author":"Johansen","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.bcp.2011.03.015_bib0250","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1182\/blood-2010-08-300756","article-title":"Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro","volume":"117","author":"Bunce","year":"2011","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.bcp.2011.03.015_bib0255","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1538-7836.2007.02491.x","article-title":"Activated protein C","volume":"5","author":"Griffin","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.bcp.2011.03.015_bib0260","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1160\/TH04-02-0112","article-title":"Do prothrombotic factors influence clinical phenotype of severe haemophilia? A review of the literature","volume":"92","author":"van Dijk","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.bcp.2011.03.015_bib0265","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1111\/j.1538-7836.2005.01639.x","article-title":"Factor V Leiden improves in vivo hemostasis in murine hemophilia models","volume":"3","author":"Schlachterman","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.bcp.2011.03.015_bib0270","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1111\/j.1538-7836.2006.02226.x","article-title":"Peptidomimetic inhibitors for activated protein C: implications for hemophilia management","volume":"4","author":"Butenas","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.bcp.2011.03.015_bib0275","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1161\/01.ATV.0000013904.40673.CC","article-title":"Regulation of functions of vascular wall cells by tissue factor pathway inhibitor: basic and clinical aspects","volume":"22","author":"Kato","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.bcp.2011.03.015_bib0280","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1046\/j.1538-7836.2003.00391.x","article-title":"The rediscovery and isolation of TFPI","volume":"1","author":"Broze","year":"2003","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.bcp.2011.03.015_bib0285","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1161\/ATVBAHA.107.141606","article-title":"The haemostatic role of tissue factor pathway inhibitor","volume":"28","author":"Crawley","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.bcp.2011.03.015_bib0290","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1160\/TH05-05-0361","article-title":"Improved coagulation in bleeding disorders by non-anticoagulant sulfated polysaccharides (NASP)","volume":"95","author":"Liu","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.bcp.2011.03.015_bib0295","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/00001721-199507000-00004","article-title":"Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced haemophilia A","volume":"6","author":"Erhardtsen","year":"1995","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.bcp.2011.03.015_bib0300","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1182\/blood-2007-07-098913","article-title":"Efficacy and safety of a new-class hemostatic drug candidate AV513, in dogs with hemophilia A","volume":"111","author":"Prasad","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2011.03.015_bib0305","doi-asserted-by":"crossref","unstructured":"Emily K. Waters, Ryan M. Genga, Michael C. Schwartz, Jennifer A. Nelson, Robert G. Schaub, Karen A. Olson, et al., Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor. Blood 2011. First Edition Paper, prepublished online March 9, 2011.","DOI":"10.1182\/blood-2010-10-311936"},{"key":"10.1016\/j.bcp.2011.03.015_bib0310","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1146\/annurev.pharmtox.010909.105547","article-title":"Discovery and development of therapeutic aptamers","volume":"50","author":"Bouchard","year":"2010","journal-title":"Annu Rev Pharmacol Toxicol"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295211001821?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295211001821?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T08:12:47Z","timestamp":1592467967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295211001821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0006295211001821"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2011.03.015","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}